Melphalan

Catalog No.S8266 Synonyms: Alkeran, Sarcolysin, L-PAM

For research use only.

Melphalan (Alkeran, Sarcolysin, L-PAM) is a phenylalanine derivative of nitrogen mustard with antineoplastic activity.

Melphalan Chemical Structure

CAS No. 148-82-3

Selleck's Melphalan has been cited by 10 Publications

1 Customer Review

Purity & Quality Control

Choose Selective DNA alkylator Inhibitors

Biological Activity

Description Melphalan (Alkeran, Sarcolysin, L-PAM) is a phenylalanine derivative of nitrogen mustard with antineoplastic activity.
In vitro

Exposure of a myeloma cell line (RPMI 8226) to a 30-minute pulse of melphalan (1-phenylalanine-mustard) results in a cell cycle progression delay characteristic for DNA cross-linking agents[1]. Melphalan has been shown to bind to DNA, RNA, and protein in cells in vitro. Melphalan induces chromosomal aberrations, sister chromatid exchange, micronuclei, mutations at the HPRT gene, and DNA damage in human cells in vitro. It also induces transformation of C3H 10T1/2 and other cells. In cultured rodent cells, it induces chromosomal aberrations, sister chromatid exchange, gene mutations, and DNA damage. In addition, it induces aneuploidy and sex-linked recessive lethal mutations in Drosophila, and mutation in bacteria[3].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C6 (Rat) Glioma cell lines M2PWeGN6fG:2b4jpZ4l1gSCjc4PhfS=> MXTUbIUh[2:vcH;1coQhf2G|IITld5Rm\CCob4KgZ5l1d3SxeHnjbZR6KGGpYXnud5QhSzZiKGLheEkhT2yrb33hJINmdGxibHnu[ZMtKEmFNUC9NVEh|ryP NFrGc5Q6OTdzOEiy
CEM T-lymphocytes MV3DfZRwfG:6aXPpeJkh[XO|YYm= MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBETU1iVD3sfY1xcG:leYTld{whUUN3ME2yMlQ4KM7:TR?= MlXDNVEyPzB4NEi=
D283 MR (human) Glioma cell lines NXTTPVl5S3m2b4TvfIlkcXS7IHHzd4F6 NH70dHFVcGViY3;tdI92dmRid3HzJJRme3SnZDDmc5Ih[3m2b4TvfIlkcXS7IHHnZYlve3RiREK4N{BOWiBqaIXtZY4qKEeuaX;tZUBk\WyuIHzpcoV{NCCLQ{WwQVE3NjNizszN MX25NVcyQDh{
D283 (human) Glioma cell lines MkPkR5l1d3SxeHnjbZR6KGG|c3H5 MnfoWIhmKGOxbYDveY5lKHejczD0[ZN1\WRiZn;yJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KER{OEOgLIh2dWGwKTDHcIlwdWFiY3XscEBtcW6nczygTWM2OD14Lkig{txO NHjnOGg6OTdzOEiy
D341 (human) Glioma cell lines M3jGZ2N6fG:2b4jpZ4l1gSCjc4PhfS=> NIHsTHhVcGViY3;tdI92dmRid3HzJJRme3SnZDDmc5Ih[3m2b4TvfIlkcXS7IHHnZYlve3RiREO0NUApcHWvYX6pJGdtcW:vYTDj[YxtKGyrbnXzMEBKSzVyPUGyMlQh|ryP NV;ETo52QTF5MUi4Ni=>
K562 NEXRPINEgXSxdH;4bYNqfHliYYPzZZk> NGD3SlQyKGh? NVTIWohtUW5idnn0do8h[3m2b4TvfIlkKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gcIV2c2WvaXOgZ4VtdCCuaX7lJGs2PjJiYX\0[ZIhcW6ldXLheIlwdiCob4KgNUBpd3W{LDDJR|UxRTNyIN88US=> NGfxeXkyOjd6MUG4PC=>
Jurkat T cells NVTueWhrS3m2b4TvfIlkcXS7IHHzd4F6 MXHJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCKdX3hckBLfXKtYYSgWEBk\WyuczygTWM2OD1{LkKg{txO NFPGdnA5PDZ2MESx
L1210 cell M3vuZ2N6fG:2b4jpZ4l1gSCjc4PhfS=> Mk[xO|IhcA>? NXXyWmdPXGW|dHXkJIlvKH[rdILvJIZweiC2aHWgZ5l1d3SxeHnjbZR6KGG|IH71cYJmeiCxZjD2bYFjdGViY3XscJMh[WejaX7zeEBNOTJzMDDj[YxtKGyrbnWgZYZ1\XJiN{KgbJIhfHKnYYTt[Y51KGG2IHPvcoMvKG:oIEGwSU03NCCLREWwQVEvPyEQvF2= NEjK[lIzPTlyMke3
LoVo cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn;XNVQ1KGi{ NWr6VFYxXGW|dHXkJIlvKH[rdILvJIZweiCrbnjpZol1cW:wIHHmeIVzKDF2NDDodkBmgHCxc4Xy[UBi\2GrboP0JIh2dWGwIHPvcI9vKGOjcnPpco9u[SCOb2\vJINmdGxibHnu[UwhUUN3ME20MlA6KM7:TR?= M1fyXFc6QTZ3NES=
MCF-7 cells Ml:5R5l1d3SxeHnjbZR6KGG|c3H5 NVLNfYpOUW5idnn0do8h[3m2b4TvfIlkcXS7IHHjeIl3cXS7IHHnZYlve3RiTVPGMVctKEmFNUC9NE4{KM7:TR?= NYSxUXVqOTF7OEW0O|k>
Molt 4/C8 cells NGH4T2ZEgXSxdH;4bYNqfHliYYPzZZk> M17GVGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1wdHRiND;DPEBk\WyuczygTWM2OD1|LkK0JO69VQ>? MlfmNVEyPzB4NEi=
P388 cells NVTwblJSS3m2b4TvfIlkcXS7IHHzd4F6 NGLicINEgXSxdH;4bYNqfHliZY\hcJVifGWmIHHnZYlve3RiUEO4PEBk\WyuczygTWM2OD1yLkKyJO69VQ>? MnrsPVc3PzZ|OR?=
MCF-7 NV[zZpljWHKxbHnm[ZJifGmxbjDhd5NigQ>? M2\le2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIlvKE2FRj23JIh2dWGwIHLy[YF{fCClYX7j[ZIh[2WubIOsJGlEPTB;NT63JO69VQ>? M1O1fFE2PjV6OEe1
C6 glioma cell line NH\OWYxEgXSxdH;4bYNqfHliYYPzZZk> MlToR5l1d3SxeHnjbZR6KGGpYXnud5QhemG2IFO2JIdtcW:vYTDj[YxtKGyrbnWsJGlEPTB;MUKuOkDPxE1? NWLKbFBnOTZ7N{C0NFk>
HCT116 cells NFOzSVREgXSxdH;4bYNqfHliYYPzZZk> NV72[oFwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|LDDJR|UxRTNyLkKg{txO NVfJd|dKOTZ7OU[2OVc>
HCT15 cells MYLDfZRwfG:6aXPpeJkh[XO|YYm= NGLhbXZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzNTDj[YxteyxiSVO1NF0{Pi5|IN88US=> MXyxOlk6PjZ3Nx?=
KM12 cells MUTDfZRwfG:6aXPpeJkh[XO|YYm= M4DqXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtOOTJiY3XscJMtKEmFNUC9OFMvPyEQvF2= Mn\WNVY6QTZ4NUe=
SW620 cells M4ezXWN6fG:2b4jpZ4l1gSCjc4PhfS=> MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTW|YzOCClZXzsd{whUUN3ME2zPE46KM7ebR?= MUexOlk6PjZ3Nx?=
HCC2998 cells NXWzNGNYS3m2b4TvfIlkcXS7IHHzd4F6 NIDwdm9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS0N{OUm4JINmdGy|LDDJR|UxRTRzLkeg{txO NUG1XotFOTZ7OU[2OVc>
SR cells NVj4XotIS3m2b4TvfIlkcXS7IHHzd4F6 M1TJOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNTKGOnbHzzMEBKSzVyPUGuPFYh|ryP Mo\VNVY6QTZ4NUe=
HSC2 cells Mlz2R5l1d3SxeHnjbZR6KGG|c3H5 MmO1R5l1d3SxeHnjbZR6KGGpYXnud5QhUFOFMjDj[YxteyxiQ1O1NF0{PSEQvF2= M4C3flE4Ozh|OEiz
HL60 cells NFv4eYtEgXSxdH;4bYNqfHliYYPzZZk> NH\YS41EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{NCCFQ{WwQVYh|ryP MWexO|M5Ozh6Mx?=
MOLT3 cells MU\GeY5kfGmxbjDhd5NigQ>? NGrwPVk4OiCq NIPVdoxCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xVOyClZXzsd{BqdiCycnXz[Y5k\SCxZjDQ[Y5q[2mubHnuMWcu[W2rZHHz[UBi\nSncjC3NkBpenNiYomgXHRVKGG|c3H5MEBKSzVyPUCuN{DPxE1? MWqxO|QyPjV|Mh?=
HepG2 cells MkHGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1XlVWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhmeEd{IHPlcIx{NCCJSUWwQVE4KM7:TR?= NU\0foZTOThyNkizOlI>
RT4 cells M3XjSmN6fG:2b4jpZ4l1gSCjc4PhfS=> M4Pielk3KGh? MkLQR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVnQ1KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDtbYNzd3SrdHXyJIF{e2G7LDDJR|UxRTF2LkK1JO69VQ>? MVexPFE5PzJ|Nx?=
RT112 cells M2rNe2N6fG:2b4jpZ4l1gSCjc4PhfS=> NWTpfIdIQTZiaB?= NIjONGpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBTXDFzMjDj[YxteyCjZoTldkA6PiCqcoOgZpkhdWmlcn;0bZRmeiCjc4PhfUwhUUN3ME20MlY6KM7:TR?= MWKxPFE5PzJ|Nx?=
5637 cells MWTDfZRwfG:6aXPpeJkh[XO|YYm= NIfaUG86PiCq NFm4PINEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckA2PjN5IHPlcIx{KGGodHXyJFk3KGi{czDifUBucWO{b4TpeIVzKGG|c3H5MEBKSzVyPUCuN|Eh|ryP NETwc2IyQDF6N{KzOy=>
KYSE70 cells M3i2T2N6fG:2b4jpZ4l1gSCjc4PhfS=> NITvZWo6PiCq M4e4XmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGt[W0V5MDDj[YxteyCjZoTldkA6PiCqcoOgZpkhdWmlcn;0bZRmeiCjc4PhfUwhUUN3ME2xOk4yPiEQvF2= MXGxPFE5PzJ|Nx?=
KYSE510 NE[wRXNEgXSxdH;4bYNqfHliYYPzZZk> NVHRcWR[QTZiaB?= NEDJ[2tEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMYVOHNUGwJINmdGy|IHHmeIVzKDl4IHjyd{BjgSCvaXPyc5RqfGW{IHHzd4F6NCCLQ{WwQVgvOThizqzt Mn3yNVgyQDd{M{e=
KYSE520 cells NHjR[3VEgXSxdH;4bYNqfHliYYPzZZk> M3;FWVk3KGh? NX\yS|k3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU1mVRUWyNEBk\WyuczDh[pRmeiB7NjDodpMh[nlibXnjdo91cXSncjDhd5NigSxiSVO1NF0yOC52OTFOwG0> MV:xPFE5PzJ|Nx?=
YAPC cells M{S2VGN6fG:2b4jpZ4l1gSCjc4PhfS=> M3f3e|k3KGh? NYfDW45vS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hYUGSQzDj[YxteyCjZoTldkA6PiCqcoOgZpkhdWmlcn;0bZRmeiCjc4PhfUwhUUN3ME21Mlk2KM7:TR?= Moq5NVgyQDd{M{e=
DAN-G cells NICybnVEgXSxdH;4bYNqfHliYYPzZZk> MX65OkBp MnTOR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSGFPNUdiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JI1q[3KxdHn0[ZIh[XO|YYmsJGlEPTB;Mj62OUDPxE1? MVWxPFE5PzJ|Nx?=
SISO cells MnLsR5l1d3SxeHnjbZR6KGG|c3H5 NEPUXXI6PiCq NIK5Z4ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUVORIHPlcIx{KGGodHXyJFk3KGi{czDifUBucWO{b4TpeIVzKGG|c3H5MEBKSzVyPUGg{txO Ml36NVgyQDd{M{e=
LCLC-103H cells MlniR5l1d3SxeHnjbZR6KGG|c3H5 MUW5OkBp MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMR2xENTFyM1igZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KG2rY4LveIl1\XJiYYPzZZktKEmFNUC9OEDPxE1? MXmxPFE5PzJ|Nx?=
MCF7 cells MlmzR5l1d3SxeHnjbZR6KGG|c3H5 MoXOPVYhcA>? NF73Z4VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFk3KGi{czDifUBucWO{b4TpeIVzKGG|c3H5MEBKSzVyPUOuO|Eh|ryP NGr4N3MyQDF6N{KzOy=>
A427 cells M2KxcWN6fG:2b4jpZ4l1gSCjc4PhfS=> NIXPZWw6PiCq M2\EeGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OjdiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JI1q[3KxdHn0[ZIh[XO|YYmsJGlEPTB;NT6xN{DPxE1? NVTvbYw3OThzOEeyN|c>
Caov3 cells NX\DeVZWS3m2b4TvfIlkcXS7IHHzd4F6 MorpO|IhcA>? MlHqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR4FwfjNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfS=> M4\LWlE6ODR4N{m0
NSCLC cells NIjs[XREgXSxdH;4bYNqfHliYYPzZZk> NELBUJE1QCCqcoO= NX\5b3EyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVlOFTFOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIgh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME22Mlc{PjB6MzFOwG0> NHTnNG4zOTF{Mkm1Ni=>
CNSC cells MV3DfZRwfG:6aXPpeJkh[XO|YYm= NH7EOlM1QCCqcoO= NY\5eVg{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS06VQzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUeuOVg2PzhizszN MV2yNVEzOjl3Mh?=
mouse FM3A/0 cells NFLrWnJRem:uaX\ldoF1cW:wIHHzd4F6 NI\2ZZc1QCCqcoO= MlT0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCITUPBM|Ah[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBi\nSncjC0PEBpenNiYomgXmYuS2:3bITldkBEd3WwdHnu[{whUUN3ME2zMlYh|ryP NEDTfIgzOTF2Nkm4OS=>
CEM/0 cells MV\Qdo9tcW[ncnH0bY9vKGG|c3H5 NEDB[3E1QCCqcoO= MojxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFRV2vNEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIFnfGW{IES4JIhzeyCkeTDaSk1Ed3WudHXyJGNwfW62aX7nMEBKSzVyPUOuOUDPxE1? MonUNlEyPDZ7OEW=
HeLa cells NETyeFVRem:uaX\ldoF1cW:wIHHzd4F6 MnjSOFghcHK| NYnrRY9ESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCpcn;3eIgh[W[2ZYKgOFghcHK|IHL5JHpHNUOxdXz0[ZIhS2:3boTpcoctKEmFNU2xMlkh|ryP M3HnU|IyOTR4OUi1
INA-6 cells NVe0eZZNS3m2b4TvfIlkcXS7IHHzd4F6 MoLrR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTW5CNTZiY3XscJMh[XO|ZYPz[YQh[XNidnnhZoxmKG[{YXP0bY9veyC3c3nu[{Bidm6neHnuJHYuTkmWQz;wdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHL5JIZtd3diY4n0c41mfHK7LDDFR|UxRTJizszN NF;lWGozOjBzOUKyPS=>
PBMC cells MWfDfZRwfG:6aXPpeJkh[XO|YYm= MmPQR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGJOSyClZXzsd{Bie3Onc4Pl[EBieyC4aXHicIUh\nKjY4Tpc45{KHW|aX7nJIFvdmW6aX6gWk1HUVSFL4Dyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYomg[oxwfyCleYTvcYV1enluIFXDOVA:OyEQvF2= NFPvc|EzOjBzOUKyPS=>
SH-SY5Y cells NEO1RmNEgXSxdH;4bYNqfHliYYPzZZk> NWH5Oo4zPzJiaB?= NETkNmZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUC2VWUXZJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PS53IN88US=> MWGyNlY{Ozh|NB?=
U251 cells NEHzR|JEgXSxdH;4bYNqfHliYYPzZZk> MmSzOUBl[Xm| M2G1d2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHUzPTFiY3XscJMh[W[2ZYKgOUBl[Xm|IHL5JG1VXCCjc4PhfUwhUUN3ME2zJO69VQ>? M17DUFI1QTByNEG4
A549 cells MmL5R5l1d3SxeHnjbZR6KGG|c3H5 MmjrOUBl[Xm| M1TCcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgOUBl[Xm|IHL5JG1VXCCjc4PhfUwhUUN3ME2zJO69VQ>? MmG2NlQ6ODB2MUi=
PANC1 cells NX3OSXFjS3m2b4TvfIlkcXS7IHHzd4F6 NXXQVHJEPSCmYYnz NVLzVlZnS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEGQQ{GgZ4VtdHNiYX\0[ZIhPSCmYYnzJIJ6KE2WVDDhd5NigSxiSVO1NF0{KM7:TR?= M{DDXlI1QTByNEG4
HT-29 cells M4PWdmN6fG:2b4jpZ4l1gSCjc4PhfS=> MnmyOUBl[Xm| MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjC1JIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUOg{txO M2fyfFI1QTByNEG4
DLD1 cells MVvDfZRwfG:6aXPpeJkh[XO|YYm= MWe1JIRigXN? M3juVGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRNTDFiY3XscJMh[W[2ZYKgOUBl[Xm|IHL5JG1VXCCjc4PhfUwhUUN3ME2zJO69VQ>? NYrod4ZxOjR7MEC0NVg>
HeLa cells Mnn4R5l1d3SxeHnjbZR6KGG|c3H5 NUTGZplyPCCmYYnz MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDDc5VtfGW{IHPveY51\XJiYX7hcJl{cXNuIFnDOVA:OS57IN88US=> MVmyN|U{Pzl2Mh?=
FM3A cells MlryR5l1d3SxeHnjbZR6KGG|c3H5 M4jad|Ih\GG7cx?= MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDGUVNCKGOnbHzzJIFnfGW{IEKg[IF6eyCkeTDDc5VtfGW{IHPveY51\XJiYX7hcJl{cXNuIFnDOVA:Oy54IN88US=> NYDSRW5wOjN3M{e5OFI>
HL-60(TB) cells MUjGeY5kfGmxbjDhd5NigQ>? NHPRSpgzPCCq M1\lemFvfGmuZYXr[Y1q[yCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJGhNNTZyKGTCLUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIIT1cY9zKGe{b4f0bEBi\nSncjCyOEBpenNuIFnDOVA:OC5|ODFOwG0> MnLrNlM2Ozd7NEK=
SR cells M3X5T2Z2dmO2aX;uJIF{e2G7 Mor3NlQhcA>? NUTPTW5KSW62aXzleYtmdWmlIHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hW1JiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1fW2xcjDndo94fGhiYX\0[ZIhOjRiaILzMEBKSzVyPUOuNlQh|ryP NX6wUZlxOjR4NUe1Olg>
L1210 cells M{PqU3Bzd2yrZnXyZZRqd25iYYPzZZk> NWP1V|BtOiCmYYnz Mn;XRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCOMUKxNEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDpcoN2[mG2ZXSg[o9zKDJiZHH5d{BjgSCFb4XseIVzKGOxdX70[ZIh[mG|ZXSgZZN{[XluIFnDOVA:QC54IN88US=> M3\Yb|I3OTRzOUGx
FM3A cells MY\Qdo9tcW[ncnH0bY9vKGG|c3H5 NF;2R4UzKGSjeYO= MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKE[PM1GgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iaX7jeYJifGWmIH\vdkAzKGSjeYOgZpkhS2:3bITldkBkd3WwdHXyJIJie2WmIHHzd4F6NCCLQ{WwQVMvPiEQvF2= NFTsboYzPjF2MUmxNS=>
CEM cells MmT5VJJwdGmoZYLheIlwdiCjc4PhfS=> M{TnclMh\GG7cx?= NIj5VXJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPFUUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDpcoN2[mG2ZXSg[o9zKDNiZHH5d{BjgSCFb4XseIVzKGOxdX70[ZIh[mG|ZXSgZZN{[XluIFnDOVA:Oy53IN88US=> NVjET28{OjZzNEG5NVE>
HeLa cells NUS4U2xLWHKxbHnm[ZJifGmxbjDhd5NigQ>? NI\6XIk1KGSjeYO= M2rSR2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXMZUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDpcoN2[mG2ZXSg[o9zKDRiZHH5d{BjgSCFb4XseIVzKGOxdX70[ZIh[mG|ZXSgZZN{[XluIFnDOVA:OS57IN88US=> NFnGbpkzPjF2MUmxNS=>
In vivo Melphalan has been tested in mice by oral, intraperitoneal, and dermal application; in rats by intraperitoneal injection, and in monkeys by oral administration. In mice, the administration of melphalan produced forestomach papillomas, lymphosarcomas, and skin and lung tumours. In rats, melphalan caused mammary gland tumours, and peritoneal sarcomas. Results in monkeys were inconclusive[3].

Protocol (from reference)

Animal Research:[2]
  • Animal Models: Tg.AC mice
  • Dosages: 0.25, 1, and 4 mg/kg weekly
  • Administration: Topical administration/oral gavage

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 305.20
Formula

C13H18Cl2N2O2

CAS No. 148-82-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04455139 Recruiting Drug: Topotecan|Drug: Melphalan Eye Cancer Retinoblastoma Prof. Beck Popovic Maja|University of Lausanne Hospitals November 15 2021 Phase 2
NCT04945954 Not yet recruiting Other: Drug: Cyclophosphamide Hematopoietic Stem Cell Transplantation Seoul National University Hospital|National Institute of Food and Drug Safety Evaluation (Republic of Korea) June 2021 Not Applicable
NCT04918511 Withdrawn Drug: OPD5 Relapse Multiple Myeloma|Multiple Myeloma Oncopeptides AB May 27 2021 Phase 1
NCT04868786 Recruiting Drug: Mycophenolate Mofetil Hematopoietic Stem Cell Transplantation Seoul National University Hospital|National Institute of Food and Drug Safety Evaluation (Republic of Korea) October 26 2020 Phase 1
NCT04937634 Recruiting Drug: Melphalan Hematopoietic Stem Cell Transplantation Seoul National University Hospital|National Institute of Food and Drug Safety Evaluation (Republic of Korea) September 11 2020 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Melphalan | Melphalan ic50 | Melphalan price | Melphalan cost | Melphalan solubility dmso | Melphalan purchase | Melphalan manufacturer | Melphalan research buy | Melphalan order | Melphalan mouse | Melphalan chemical structure | Melphalan mw | Melphalan molecular weight | Melphalan datasheet | Melphalan supplier | Melphalan in vitro | Melphalan cell line | Melphalan concentration | Melphalan nmr